PCM
XBIT icon

Penserra Capital Management’s XBiotech XBIT Stock Holding History

Penserra Capital Management’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-695
Closed -$9K – 1569
2021
Q3 		$9K Buy
695
+10
+1% +$159 ﹤0.01% 1372
2021
Q2 		$11K Buy
685
+20
+3% +$339 ﹤0.01% 1268
2021
Q1 		$11K Sell
665
-5
-0.7% -$93 ﹤0.01% 1031
2020
Q4 		$10K Buy
670
+422
+170% +$7.78K ﹤0.01% 928
2020
Q3 		$4K Buy
+248
New +$4.28K ﹤0.01% 872

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Penserra Capital Management's XBIT Position: Q4 2021 in Review

Penserra Capital Management sold out of XBiotech (XBIT) in Q4 2021, closing a stake of 695 shares — an estimated $9K sold.

Penserra Capital Management first reported a position in XBIT in Q3 2020 and held it in 5 quarters. The position peaked at $11K in Q2 2021. 61 funds tracked by Wall St. Rank hold XBIT as of Q4 2021.

  • Penserra Capital Management reported no remaining XBiotech position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 695 XBiotech shares in Q4 2021, an estimated $9K.
  • Penserra Capital Management first reported a position in XBiotech in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's XBiotech position peaked at $11K in Q2 2021.
  • 61 funds tracked by Wall St. Rank held XBiotech as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.